Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

For adults with diabetes and obesity, GLP-1 RAs are associated with a reduced risk for obesity-related cancer compared with DPP-4 inhibitors.

Despite her active and healthy lifestyle, Sasha Barden felt stuck in her weight loss journey. She decided to try GLP-1 medications to support her weight loss goal. After six months on Wegovy ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced ...

GLP-1 receptor agonists may aid smoking cessation by curbing cravings and mitigating weight gain, which often are impediments in quitting, according to a presentation at the American Psychiatric ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

retrospective cohort study based on electronic medical records data to compare the incidence of ORC in adults (≥24 years) living with obesity and diabetes who were treated with a first-generation ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric adverse events ...

Starting Jan. 1, Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, will dramatically change how and when it pays for Zepbound— the insurer’ s preferred GLP-1 ...